Miglitol

• CAT Number: A000308
• CAS Number: 72432-03-2
• Molecular Formula: C₈H₁₇NO₅
• Molecular Weight: 207.22
• Purity: ≥95%
• Synonyms: 72432-03-2; Glyset; Diastabol; (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol; Miglitolum
• Target: alpha-glucosidase inhibitor
• Storage: -20°C
• InChI: InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1
• InChIKey: IBAQFPQHRJAVAV-ULAWRXDQSA-N
• SMILES: C1C(C(C(C(N1CCO)CO)O)O)O

Miglitol, also known as BAY1099; Seibule; Diastabol; Glyset, is an alpha-glucosidase inhibitor. Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to break down complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.

Reference

1: Amagai M, Tsuchiya H, Chiba Y, Suzuki J, Nagakura J, Shigematsu E, Yamakawa T,
Terauchi Y. Incretin Kinetics Before and After Miglitol in Japanese Patients With
Late Dumping Syndrome. J Clin Med Res. 2017 Oct;9(10):879-885. doi:
10.14740/jocmr3135w. Epub 2017 Sep 1. PubMed PMID: 28912925; PubMed Central
PMCID: PMC5593436.

2: Shimabukuro M, Tanaka A, Sata M, Dai K, Shibata Y, Inoue Y, Ikenaga H,
Kishimoto S, Ogasawara K, Takashima A, Niki T, Arasaki O, Oshiro K, Mori Y,
Ishihara M, Node K; Collaborators on the Effect of Miglitol on Glucose Metabolism
in Acute Coronary Syndrome (MACS) Study. α-Glucosidase inhibitor miglitol
attenuates glucose fluctuation, heart rate variability and sympathetic activity
in patients with type 2 diabetes and acute coronary syndrome: a multicenter
randomized controlled (MACS) study. Cardiovasc Diabetol. 2017 Jul 6;16(1):86.
doi: 10.1186/s12933-017-0571-1. PubMed PMID: 28683829; PubMed Central PMCID:
PMC5501494.

3: Kishida Y, Okubo H, Ohno H, Oki K, Yoneda M. Effect of miglitol on the
suppression of nonalcoholic steatohepatitis development and improvement of the
gut environment in a rodent model. J Gastroenterol. 2017 Nov;52(11):1180-1191.
doi: 10.1007/s00535-017-1331-4. Epub 2017 Mar 27. PubMed PMID: 28349245.

4: Dash RP, Babu RJ, Srinivas NR. Reappraisal and perspectives of clinical
drug-drug interaction potential of α-glucosidase inhibitors such as acarbose,
voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica.
2017 Jan 19:1-20. doi: 10.1080/00498254.2016.1275063. [Epub ahead of print]
PubMed PMID: 28010166.

5: Osonoi T, Saito M, Hariya N, Goto M, Mochizuki K. Add-on therapy with
anagliptin in Japanese patients with type-2 diabetes mellitus treated with
metformin and miglitol can maintain higher concentrations of biologically active
GLP-1/total GIP and a lower concentration of leptin. Peptides. 2016
Dec;86:118-125. doi: 10.1016/j.peptides.2016.10.011. Epub 2016 Oct 22. PubMed
PMID: 27780736.

6: Balakumaran K, Janagili M, Rajana N, Papureddy S, Anireddy J. Development and
Validation of Miglitol and Its Impurities by RP-HPLC and Characterization Using
Mass Spectrometry Techniques. Sci Pharm. 2016 Oct 14;84(4):654-670. PubMed PMID:
27754407; PubMed Central PMCID: PMC5198025.

7: Yin Q, Wang L, Sun C. Rapid identification of miglitol and its isomers by
electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom.
2016 Aug;30 Suppl 1:155-61. doi: 10.1002/rcm.7618. PubMed PMID: 27539431.

8: Hirose S, Iwahashi Y, Seo A, Sumiyoshi M, Takahashi T, Tamori Y. Concurrent
Therapy with a Low-carbohydrate Diet and Miglitol Remarkably Improved the
Postprandial Blood Glucose and Insulin Levels in a Patient with Reactive
Hypoglycemia due to Late Dumping Syndrome. Intern Med. 2016;55(9):1137-42. doi:
10.2169/internalmedicine.55.5655. Epub 2016 May 1. PubMed PMID: 27150868.

9: Shibata E, Aoki K, Tajima K, Taguri M, Terauchi Y. Comparison of efficacy and
safety of taking miglitol dissolved in water during a meal and taking a miglitol
tablet just before a meal in patients with type 2 diabetes. Expert Opin
Pharmacother. 2016;17(7):889-94. doi: 10.1517/14656566.2016.1159297. Epub 2016
Mar 17. PubMed PMID: 26918556.

10: Sugimoto S, Nakajima H, Kosaka K, Hosoi H. Review: Miglitol has potential as
a therapeutic drug against obesity. Nutr Metab (Lond). 2015 Dec 1;12:51. doi:
10.1186/s12986-015-0048-8. eCollection 2015. Review. PubMed PMID: 26628904;
PubMed Central PMCID: PMC4666030.